NCT05171803

Brief Summary

The purpose of this protocol is to investigate the ability of pre-existing immunity by natural infection or vaccination to prevent infections by emerging SARS-CoV-2 variants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 29, 2021

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 16, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 29, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2023

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

1.6 years

First QC Date

December 16, 2021

Last Update Submit

November 6, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessing immunity

    Assess immune escape among people with vaccination or natural immunity

    1 year

Interventions

No intervention, prospective, cohort study.

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults living in Los Angeles County

You may qualify if:

  • People who have been fully vaccinated for COVID-19 2-12 weeks prior to enrollment or individuals \<3 months post-COVID-19 infection.
  • Collection of samples for blood samples will be done only from healthy, nonpregnant adults who weigh at least 110 pounds.
  • Participants must be able to provide informed consent.

You may not qualify if:

  • Subjects considered vulnerable including children, pregnant women, nursing home residents, or other institutionalized persons, fetuses, prisoners, and persons without decisional capacity.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Curative

San Dimas, California, 91773, United States

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 16, 2021

First Posted

December 29, 2021

Study Start

May 29, 2021

Primary Completion

December 31, 2022

Study Completion

October 15, 2023

Last Updated

November 8, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

This will not be available.

Locations